Green Thumb Industries (GTII) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
18 Jun, 2025Market landscape and growth outlook
U.S. cannabis market projected to reach ~$100B by 2030, rivaling alcohol and tobacco industries.
Cannabis expected to have a 12% CAGR through 2027, outpacing beer, tobacco, spirits, and wine.
70% of Americans support legalization, with significant legislative momentum and new states legalizing adult-use and medical cannabis since 2022.
Legal cannabis generates more tax revenue than alcohol in established markets and supports over 440,000 jobs.
Company overview and strategy
Operates 104 retail stores across 14 states, serving 50% of American adults as of May 2025.
Employs 4,900 team members and emphasizes community engagement and giving back.
Focused on high-demand, limited-supply markets with a dual-pronged growth strategy and disciplined capital allocation.
Maintains a strong balance sheet to fund strategic growth initiatives.
Brand portfolio and retail experience
Portfolio includes RYTHM, incredibles, Dogwalkers, Beboe, Señorita, Shine, and Doctor Solomon's, covering flower, vape, edibles, pre-rolls, beverages, and health/beauty.
Flower leads with 41.7% category share and 8% YoY growth; beverages and pre-rolls show strong double-digit growth.
1.4M+ loyalty members and omni-channel retail experience with digital, delivery, and in-store integration.
Consistent national retail brand and pipeline of licenses to expand footprint.
Latest events from Green Thumb Industries
- Revenue rose 3.4% in 2025, with strong cash flow and retail expansion offset by margin pressure.GTII
Q4 202525 Feb 2026 - Q2 revenue up 4.7% to $293.3M, but margins pressured by price compression and regulatory headwinds.GTII
Q2 20253 Feb 2026 - Q2 revenue up 11% to $280M, net income $21M, adjusted EBITDA $94M; strong retail growth.GTII
Q2 20242 Feb 2026 - Q3 revenue up 4% to $287M, Adjusted EBITDA $89M, $150M credit facility, four new stores opened.GTII
Q3 202415 Jan 2026 - Record revenue, EBITDA, and cash flow drive growth amid pricing and regulatory challenges.GTII
Q4 202423 Dec 2025 - All resolutions, including board elections and plan amendments, passed with no shareholder questions.GTII
AGM 202516 Dec 2025 - Revenue up 1.4% to $280M, but margins and net income pressured by competition and pricing.GTII
Q1 202524 Nov 2025 - Q3 2025 saw modest revenue growth, strong cash flow, and continued share repurchases.GTII
Q3 20255 Nov 2025